Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator
about
Resistance to RevM10 inhibition reflects a conformational switch in the HIV-1 Rev response element.Combinatorial RNA-based gene therapy for the treatment of HIV/AIDSMode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replicationDecoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev proteinSelection and characterization of human immunodeficiency virus type 1 mutants that are resistant to inhibition by the transdominant negative RevM10 proteinIsolation of efficient antivirals: genetic suppressor elements against HIV-1.HIV-1 pathogenesis and therapeutic intervention in the SCID-hu Thy/Liv mouse: a model for primary HIV-1 infection in the human thymus.Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.Exchange of the basic domain of human immunodeficiency virus type 1 Rev for a polyarginine stretch expands the RNA binding specificity, and a minimal arginine cluster is required for optimal RRE RNA binding affinity, nuclear accumulation, and trans-An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production.Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein.Is gene therapy a good therapeutic approach for HIV-positive patients?Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individualsHIV Rev Assembly on the Rev Response Element (RRE): A Structural PerspectiveTransduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term cultureInhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteinsNonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cellsInhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.Dominant negative inhibition by fragments of a monomeric enzyme.Evidence for specific nucleocytoplasmic transport pathways used by leucine-rich nuclear export signals.New approach for inhibiting Rev function and HIV-1 production using the influenza virus NS1 proteinExpression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients.Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma.Cell-based gene therapy against HIV.A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replicationFunctional analysis of the human immunodeficiency virus type 1 Rev protein oligomerization interface.Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants.Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines.Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy.Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes.RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replicationCell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory geneComparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.Assessing genetic-based therapies for AIDS using the simian immunodeficiency virus.Cellular cofactors of lentiviral integrase: from target validation to drug discovery.A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycleCell and Gene Therapy for HIV Cure.
P2860
Q24652856-B9D9F6D7-77A7-47F2-AF68-056E0B008F6CQ26866145-B6BA3687-2A8E-4712-A6EE-1CECCC73CF64Q28368266-8005D856-F21F-4028-80B1-5DE60DD47F18Q28379462-376A6ADA-0331-44A5-A4D0-86822CBA8D58Q30304057-63A85BA8-AD72-495E-B0C8-4044FCF35053Q30701530-02F4ACD9-64E5-49D0-B007-E99A1875FA70Q33682963-5C2A9BAF-C462-4522-A521-2D22C699B04AQ33784907-0F23396F-D3B7-4632-BBE6-EB0E3705336FQ33866139-D3AEDDBF-C8C1-4E4E-B4BC-4F5632750D7AQ33967157-AFC02130-5FC9-442D-94EC-954870059178Q33988828-B30A801C-96A0-45BB-A020-542F74E735EEQ34121209-5B4B3295-C9E0-45C7-95DC-55A1FF54E93EQ34353375-EC6FCED4-627C-4A42-B80E-4634CB809EFBQ35663424-EDB845AC-EFDC-492A-9656-F83CB3003B19Q35800195-76CC9E6B-A687-448D-AA3E-3CF25615E6A8Q35808679-A7535407-6E7D-460A-98E7-A4DC2DD1470BQ35863619-22BE06BD-28C2-4584-8EC3-FFE3B540AD7BQ35865426-CA274C76-DC29-4F0A-9732-AF9CFB882800Q35924105-F6472E59-BC36-44DA-BD2F-0A51A4124298Q36638137-31684ED6-821F-4FD1-A9EF-7B1C2A1CC1FAQ37040945-2EBC84A2-9386-42E5-AFAC-44994F61C0FDQ37202345-D75439A9-A1A9-4E14-8BE9-E0CB02976D51Q37375546-9603539E-D497-408D-B41C-CFB6D4E67F18Q37679611-492A5C77-952F-4A2A-9E10-A39AB2919842Q38312987-FC3C163D-1D22-425D-8402-A632FC1D384EQ38529069-BD13D3DC-1F1A-4B62-964B-E852F3CE9F59Q39214476-B5AF8BED-C393-4A1A-8B9B-1A509B68748BQ39577700-D1382122-B6C6-4F4F-A5DF-11E81EB5A5E8Q39579073-59441599-9FA7-4D57-8CFC-6D2AB3122A2CQ39871345-E22E5597-6AAD-4CFD-A993-A365C0722A94Q39876857-F6D3A248-B590-4935-8401-E1C9B30E36F1Q39877082-754D113D-8941-4234-A633-56D4E624C23DQ39877337-4B587F9B-1CCF-4A51-BD8F-125EAC9A06C7Q39879985-D4B4D4D1-FC62-435D-ABB7-89DC8E55305AQ39881018-505AB030-68BA-4FF0-ABC9-AA5CBBD047EDQ40045233-DBFCAAC2-B93B-4C15-83E4-B4828FF7D207Q41347539-6348FFF5-9B72-4065-AEC6-FB97B65624D9Q42277905-9F72CA2D-554B-4A40-9626-172ED3957907Q42546287-D0986823-4CF1-4350-974C-7B78BEEFB36EQ47236016-8D6C77CF-944C-4976-85A2-12DDA5F80774
P2860
Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1992
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of human immunodefi ...... t-negative Rev trans-activator
@en
Inhibition of human immunodefi ...... -negative Rev trans-activator.
@nl
type
label
Inhibition of human immunodefi ...... t-negative Rev trans-activator
@en
Inhibition of human immunodefi ...... -negative Rev trans-activator.
@nl
prefLabel
Inhibition of human immunodefi ...... t-negative Rev trans-activator
@en
Inhibition of human immunodefi ...... -negative Rev trans-activator.
@nl
P2093
P2860
P356
P1476
Inhibition of human immunodefi ...... t-negative Rev trans-activator
@en
P2093
P2860
P304
P356
10.1073/PNAS.89.20.9870
P407
P577
1992-10-01T00:00:00Z